neratinib

An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
BACKGROUND Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
 
Is this relevant?
Highly Cited
2014
Highly Cited
2014
PURPOSE Human epidermal growth factor (HER) -mediated signaling is critical in many cancers, including subsets of breast and lung… (More)
Is this relevant?
2013
2013
Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients. However, a significant… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
UNLABELLED Data from 8 breast cancer genome-sequencing projects identified 25 patients with HER2 somatic mutations in cancers… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 3
  • figure 4
Is this relevant?
2011
2011
ErbB2 is frequently activated in tumors, and influences a wide array of cellular functions, including proliferation, apoptosis… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE The dose-limiting toxicities, maximum tolerated dose, pharmacokinetic profile, and preliminary antitumor activity of… (More)
  • table 1
  • table 2
  • table 3
  • table 2
  • table 3
Is this relevant?
Review
2009
Review
2009
Most advanced non-small-cell lung cancers (NSCLCs) with activating epidermal growth factor receptor (EGFR) mutations (exon 19… (More)
  • table 1
  • figure 1
  • table 2
Is this relevant?
2009
2009
1004 Background: Neratinib (HKI-272) is an orally administered irreversible pan-ErbB receptor tyrosine kinase inhibitor. In an… (More)
Is this relevant?